Liraglutide monthly Depot
Product Description
Nanexa AB
-
SE -
2024On CPHI since
-
2Certificates
-
25 - 49Employees
Company types
Primary activities
Categories
Specifications
Nanexa AB
-
SE
-
2024On CPHI since
-
2Certificates
-
25 - 49Employees
Company types
Primary activities
Nanexa AB resources (1)
-
News Nanexa’s Phase I trial of NEX-22 in type 2- diabetes progresses with next dose group according to plan
Nanexa AB today announces that the company's Phase 1 study for type 2 diabetes continues dose escalation according to plan with their long-acting depot formulation of the GLP-1 analog liraglutide.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance